Alexandra Gerlach, Associate Editor

John Buse, MD, PhD discusses the expanding role of GLP-1 receptor agonists in treatment of cardiovascular conditions.

Christian Ruff, MD, highlights abelacimab’s potential to significantly reduce bleeding in patients with high-risk atrial fibrillation.

Marc Bonaca, MD, PHH, FACC discussed semaglutide’s potential benefits for non-diabetic patients with peripheral artery disease.

Colorectal cancer cases are on the rise—here is everything you need to know as an oncology pharmacist.

Aromatase inhibitors were superior to tamoxifen in reducing risk of contralateral breast cancer.

Patients with chronic lymphocytic leukemia (CLL) show weakened T-cell memory responses to COVID-19 vaccination.

The findings provide a deeper understanding of the mechanisms underlying breast cancer progression and treatment resistance.

Adding daratumumab improved minimal residual disease (MRD) negativity rates, leading to superior progression-free survival (PFS).

Patients achieved statistically significant benefits in progression-free survival and overall response rates.

The study aims to address lingering public concerns, but its findings and communication have the potential to impact vaccine confidence and public health efforts.

Patients with central nervous system (CNS) involvement achieved favorable outcomes with chimeric antigen receptor (CAR) T-cell therapy.

Sjögren's disease is one of the most common chronic autoimmune diseases that affects 4 million individuals around the world.

The agent is the only approved therapy designed to address the underlying mechanisms of the disease.

BeeR is a bacterial protein from the family Verrucomicrobiota that influences cell shape and division.

As demand for GLP-1 therapies grows, patients face rising costs and restrictive insurance policies.

The combination was approved for treatment of patients with gastroesophageal junction (GEJ) adenocarcinoma.

Exidavnemab is a novel monoclonal antibody with disease-modifying potential.

Reducing the dose of ibrutinib following adverse events improved tolerability without compromising clinical efficacy in chronic lymphocytic leukemia (CLL).

The findings extend prior data underscoring the clinical benefit of the agent and its place in global clinical practice guidelines.

A phase 2 study showed that elotuzumab combined with pomalidomide, bortezomib, and dexamethasone was safe and efficacious.

The patient is the first to be cured using lovotibeglogene autotemcel, a novel cell-based gene therapy.

Tarlatamab was approved by the FDA in May 2024 for patients who progressed after platinum-based chemotherapy.

This marks steps toward improving health care pricing transparency, but further reforms are needed to reduce costs long-term.

Lipid metabolism plays a critical role in the function of T-cells.

The Western diet was associated with increased risk of lung cancer.

Approximately 10% of patients with multiple myeloma have pathogenic germline variants, indicating a hereditary risk.

Use of dexamethasone over tocilizumab was associated with significant cost-savings for patients with relapsed/refractory multiple myeloma (RRMM).

Vepdegestrant is an experimental oral PROteolysis TArgeting Chimera that degrades estrogen receptor (ER) in patients with metastatic breast cancer.

The favorable outcomes were observed in the phase 3 AMPLIFY trial.

The outbreak has grown to a total of 222 confirmed cases of measles, as well as 2 measles-associated deaths.